Aneeza Hamizan

and 7 more

ABSTRACT Background: Nasal endoscopic features of post nasal drip (PND) is well described but not formally studied. This study aims to assess the nasal endoscopic features of PND among rhinitis. Design: Cross-sectional study Settings: Otorhinolaryngology (ORL) outpatient clinic at a tertiary referral center. Participants: Adults (18 years and older) with chronic rhinitis grouped into either “Rhinitis with PND” or “Rhinitis only”. Main outcome measures: The endoscopic features of PND were scored as: Secretions in the posterior nasal cavity (Yes/no), erythema in the nasopharynx (none, roof only, diffuse), hemorrhagic spots (yes/no) and granular posterior pharyngeal wall(patchy/diffuse) and compared between groups. Results: There were 98 patients included (age 32.32±11.33, 61.2 % female, 61.2% PND). Presence of secretions in the posterior nasal cavity was associated with PND (“Rhinitis with PND” vs “Rhinitis only”, 78.3 v 55.3%, p=0.02). This gave 78.3% sensitivity and likelihood ratio positive of 1.41 to predict bothersome PND among rhinitis patients. The other nasal endoscopic features were not associated with PND. Conclusion: Secretions in posterior nasal cavity supports PND among rhinitis patients. Further studies to assess the endoscopic features of PND in other patient populations are needed. Keywords: laryngopharyngeal reflux, postnasal drip, rhinitis, nasal endoscopic, bothersome, inflammation, reflux symptoms index, reflux findings score Key points: rhinitis, nasal endoscopic features, postnasal drip sign, secretions posterior nasal cavity, quality of life

Luqman Rosla

and 3 more

Introduction: Immunotherapy has proven its efficacy in multiple randomized control trials (RCT) in treating allergic rhinitis (AR) as it induces induces long term remission after discontinuation and prevent new sensitization. Objective: Our aim is to look into earliest improvement of quality of life (QOL) in AR patient treated with Sublingual immunotherapy (SLIT). Methodology: Patients who were sensitized to dust mites (Dermatophagoides farinae, Dermatophagoides pteronyssinus and Blomia tropicalis) were enrolled into the study. All patients were treated with SLIT for 6 months. The patients were assessed using rhinoconjunctivitis quality of life questionnaires (RQLQ) and peak nasal inspiratory flow (PNIF) pre-treatment at 1, 3 and 6 months post SLIT. The usage of intranasal corticosteroids (INS) and antihistamine were documented in medication diary. The data for pre and post treatment for RQLQ results were analysed using paired T-test and medication diary were analysed using ANOVA test. Results: A total of 53 patients were enrolled in the study. The mean RQLQ score showed significant result at 3 and 6 months post SLIT (p<0.05). Significant improvement seen in the mean PNIF value pre-treatment (81.54 L/min ±29.36 ) compared to mean PNIF value at 3 months (92.0L/min ±29.03 ) and 6 months (96.13L/min ±26.67) post SLIT (p<0.05). The dependency of patients towards pharmacotherapy also showed a significant reduction at 3 and 6 months post SLIT (p<0.05). Conclusion: Our study showed a significant improvement of patients’ quality of life as early as 3 months of post SLIT treatment.

Salina Husain

and 3 more